New Insights into Infections due to Multidrug Resistant Gram Negative Bacteria: The Interplay between Lab and Clinic.
作者信息
Oliva Alessandra, Giacobbe Daniele Roberto, Di Luca Mariagrazia, Miller Nancy S
机构信息
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
University of Genoa and Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.
出版信息
Biomed Res Int. 2018 Dec 25;2018:8905874. doi: 10.1155/2018/8905874. eCollection 2018.
Abstract
摘要
相似文献
1
New Insights into Infections due to Multidrug Resistant Gram Negative Bacteria: The Interplay between Lab and Clinic.
Biomed Res Int. 2018 Dec 25;2018:8905874. doi: 10.1155/2018/8905874. eCollection 2018.
2
Multidrug-resistant (MDR) Gram-negative bacteria information leaflets.
J Hosp Infect. 2016 Jan;92(1):86-7. doi: 10.1016/j.jhin.2015.08.014.
3
Multidrug-Resistant Gram-Negative Organisms (MDRGNO) Information for patients, relatives and visitors.
J Hosp Infect. 2016 Jan;92(1):88-91.
4
Multidrug-Resistant Gram-Negative Organisms (MDRGNO): Information for healthcare workers.
J Hosp Infect. 2016 Jan;92(1):92-4. doi: 10.1016/j.jhin.2015.08.008.
5
Colistin for the treatment of multidrug-resistant infections.
Lancet Infect Dis. 2018 Nov;18(11):1174-1175. doi: 10.1016/S1473-3099(18)30611-X. Epub 2018 Oct 24.
6
[Monotherapy vs. combined therapy in the treatment of multi-drug resistance gramnegative bacteria].
Rev Esp Quimioter. 2016 Sep;29 Suppl 1:43-6.
7
Enhancing antibiotic activity to combat resistant Gram-negative bacteria: what's next?
Future Med Chem. 2014;6(17):1849-51. doi: 10.4155/fmc.14.128.
8
Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
Int J Antimicrob Agents. 2019 Mar;53(3):211-224. doi: 10.1016/j.ijantimicag.2018.10.011. Epub 2018 Oct 27.
9
Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661.
10
The role of PK/PD-based strategies to preserve new molecules against multi-drug resistant gram-negative strains.
J Chemother. 2020 Sep;32(5):219-225. doi: 10.1080/1120009X.2020.1786634. Epub 2020 Jul 6.
引用本文的文献
1
Risk factors for colonization with multidrug-resistant Gram-negative bacteria and in Long Term Care Facilities (LTCFs) residents: the evidence from 27 facilities in a high endemic setting.
Front Cell Infect Microbiol. 2023 Jun 12;13:1155320. doi: 10.3389/fcimb.2023.1155320. eCollection 2023.
2
Filamentous Thermosensitive Mutant Z: An Appealing Target for Emerging Pathogens and a Trek on Its Natural Inhibitors.
Biology (Basel). 2022 Apr 20;11(5):624. doi: 10.3390/biology11050624.
3
Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review.
Front Cell Infect Microbiol. 2021 Apr 23;11:601968. doi: 10.3389/fcimb.2021.601968. eCollection 2021.
本文引用的文献
1
Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections.
Curr Opin Infect Dis. 2018 Dec;31(6):566-577. doi: 10.1097/QCO.0000000000000493.
2
High Potency of Essential Oil against Multi-Drug Resistant Gram-Negative Bacteria and Methicillin-Resistant .
Molecules. 2018 Oct 9;23(10):2584. doi: 10.3390/molecules23102584.
3
Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control.
Expert Rev Anti Infect Ther. 2018 Oct;16(10):749-761. doi: 10.1080/14787210.2018.1522249. Epub 2018 Sep 19.
4
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.
Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576.
5
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492.
6
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
7
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Clin Microbiol Rev. 2018 Feb 14;31(2). doi: 10.1128/CMR.00079-17. Print 2018 Apr.
8
Management of KPC-producing Klebsiella pneumoniae infections.
Clin Microbiol Infect. 2018 Feb;24(2):133-144. doi: 10.1016/j.cmi.2017.08.030. Epub 2017 Sep 9.
9
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
J Antimicrob Chemother. 2017 Jul 1;72(7):1981-1984. doi: 10.1093/jac/dkx084.
10
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
Zotero 插件